Survivorship in AML – a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593–606.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379–389.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terre C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004;101(8):1712–1719.
   PubMed Web of Science ®Google Scholar
• Harrington CB, Hansen JA, Moskowitz M, et al. It's not over when it's over: long-term symptoms in cancer survivors-a systematic review. Int J Psychiatry Med. 2010;40(2):163–181.
   PubMed Web of Science ®Google Scholar
• Mehnert A, Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res. 2008;64(4):383–391.
   PubMed Web of Science ®Google Scholar
• Damlaj M, El Fakih R, Hashmi SK. Evolution of survivorship in lymphoma, myeloma and leukemia: metamorphosis of the field into long term follow-up care. Blood Rev. 2019;33:63–73.
   PubMed Web of Science ®Google Scholar
• Yabroff KR, Lawrence WF, Clauser S, et al. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–1330.
   PubMed Web of Science ®Google Scholar
• Reinhart CA, Sae-Hau M, Lee CA, et al. Blood cancer survivorship in NCI-Designated Cancer Centers: a study of services, gaps, and access barriers. J Cancer Surviv. 2020;14(1):43–47.
   PubMed Web of Science ®Google Scholar
• Hewitt M, Greenfield S, Stovall E, et al. From cancer patient to cancer survivor: lost in transition. Washington, DC: The National Academy Press; 2006.
   Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379(25):2438–2450.
   PubMed Web of Science ®Google Scholar
• de Lima M, Strom SS, Keating M, et al. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997;90(12):4719–4724.
   PubMed Web of Science ®Google Scholar
• Khera N, Storer B, Flowers ME, et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(1):71–77.
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2017. Natl Vital Stat Rep. 2019;68(7):1–66.
   PubMedGoogle Scholar
• Ostchega Y, Fryar CD, Nwankwo T, et al. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief. 2020;(364):1–8.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Atlanta (GA): Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
   Google Scholar
• Brody DJ, Pratt LA, Hughes JP. Prevalence of depression among adults aged 20 and over: United States, 2013–2016. NCHS Data Brief. 2018;303:1–8.
   PubMedGoogle Scholar
• Donin N, Filson C, Drakaki A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer. 2016;122(19):3075–3086.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Kantarjian HM, O'Brien S, et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019;109(5):545–552.
   PubMed Web of Science ®Google Scholar
• Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203–2210.
   PubMed Web of Science ®Google Scholar
• Verma D, Kantarjian H, Faderl S, et al. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010;51(5):778–782.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Wang F, Loghavi S, et al. Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? Blood Cancer J. 2019;9(2):7.
   PubMedGoogle Scholar
• Zhang H, Savage S, Schultz AR, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nat Commun. 2019;10(1):244.
   PubMedGoogle Scholar